Review



human primary ovarian cancer cell a2780  (CancerTools Org)


Bioz Verified Symbol CancerTools Org is a verified supplier
Bioz Manufacturer Symbol CancerTools Org manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    CancerTools Org human primary ovarian cancer cell a2780
    Human Primary Ovarian Cancer Cell A2780, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 94/100, based on 2780 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human primary ovarian cancer cell a2780/product/CancerTools Org
    Average 94 stars, based on 2780 article reviews
    human primary ovarian cancer cell a2780 - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    cisplatin resistant a2780 ddp sub line  (ATCC)
    99
    ATCC cisplatin resistant a2780 ddp sub line
    Cisplatin Resistant A2780 Ddp Sub Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cisplatin resistant a2780 ddp sub line/product/ATCC
    Average 99 stars, based on 1 article reviews
    cisplatin resistant a2780 ddp sub line - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    human primary ovarian cancer cell a2780  (CancerTools Org)
    94
    CancerTools Org human primary ovarian cancer cell a2780
    Human Primary Ovarian Cancer Cell A2780, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human primary ovarian cancer cell a2780/product/CancerTools Org
    Average 94 stars, based on 1 article reviews
    human primary ovarian cancer cell a2780 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    a2780  (ATCC)
    96
    ATCC a2780
    (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), <t>A2780</t> (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.
    A2780, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a2780/product/ATCC
    Average 96 stars, based on 1 article reviews
    a2780 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    a2780  (CancerTools Org)
    94
    CancerTools Org a2780
    (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), <t>A2780</t> (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.
    A2780, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a2780/product/CancerTools Org
    Average 94 stars, based on 1 article reviews
    a2780 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    a2780 cells  (CLS Cell Lines Service GmbH)
    93
    CLS Cell Lines Service GmbH a2780 cells
    (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), <t>A2780</t> (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.
    A2780 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a2780 cells/product/CLS Cell Lines Service GmbH
    Average 93 stars, based on 1 article reviews
    a2780 cells - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    a2780  (CLS Cell Lines Service GmbH)
    94
    CLS Cell Lines Service GmbH a2780
    (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), <t>A2780</t> (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.
    A2780, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a2780/product/CLS Cell Lines Service GmbH
    Average 94 stars, based on 1 article reviews
    a2780 - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), A2780 (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.

    Journal: bioRxiv

    Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

    doi: 10.64898/2026.04.20.719456

    Figure Lengend Snippet: (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), A2780 (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.

    Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

    Techniques: Conjugation Assay

    (A) Representative histograms of DNA content (PI staining) in only negative control and MTX-5-FU-Gem-miR-15a treatment showing cell cycle distribution in SK-OV-3, OVCAR-3, A2780, and UWB1.289 cells following treatment. (B) Quantification of cell cycle distribution after treatment shown as fold change in G2/S ratio relative to negative control across cell lines. (C) Representative Annexin V/PI flow cytometry plots showing apoptosis in indicated cell lines. (D) Quantification of apoptotic cells (early + late apoptosis) shown as fold change relative to control. (E) Western blot analysis showing expression of cleaved PARP, BCL-2, BAX, and BAK following treatment; β-actin serves as a loading control. Data represent mean ± SD from n = 3 biological replicates. Statistical significance between two groups was determined using two-tailed Student’s t test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Journal: bioRxiv

    Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

    doi: 10.64898/2026.04.20.719456

    Figure Lengend Snippet: (A) Representative histograms of DNA content (PI staining) in only negative control and MTX-5-FU-Gem-miR-15a treatment showing cell cycle distribution in SK-OV-3, OVCAR-3, A2780, and UWB1.289 cells following treatment. (B) Quantification of cell cycle distribution after treatment shown as fold change in G2/S ratio relative to negative control across cell lines. (C) Representative Annexin V/PI flow cytometry plots showing apoptosis in indicated cell lines. (D) Quantification of apoptotic cells (early + late apoptosis) shown as fold change relative to control. (E) Western blot analysis showing expression of cleaved PARP, BCL-2, BAX, and BAK following treatment; β-actin serves as a loading control. Data represent mean ± SD from n = 3 biological replicates. Statistical significance between two groups was determined using two-tailed Student’s t test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

    Techniques: Staining, Negative Control, Flow Cytometry, Control, Western Blot, Expressing, Two Tailed Test